An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Arms (1)

1. type

   EXPERIMENTAL

   label

   Venetoclax

   description

   Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.

   interventionNames

   1. Drug: Venetoclax

Primary outcomes (1)

1. measure

   Number of Participants With Adverse Events

   timeFrame

   From first dose of study drug until 30 days following last dose of study drug (up to approximately 5 years).

   description

   An adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.